These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 30830207)

  • 1. Assessment of Plasma Total Tau Level as a Predictive Biomarker for Dementia and Related Endophenotypes.
    Pase MP; Beiser AS; Himali JJ; Satizabal CL; Aparicio HJ; DeCarli C; Chêne G; Dufouil C; Seshadri S
    JAMA Neurol; 2019 May; 76(5):598-606. PubMed ID: 30830207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease.
    Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Lantero Rodríguez J; Snellman A; Suárez-Calvet M; Blennow K; Zetterberg H; Schöll M;
    JAMA Neurol; 2021 Apr; 78(4):396-406. PubMed ID: 33427873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in Alzheimer Disease Blood Biomarkers and Associations With Incident All-Cause Dementia.
    Lu Y; Pike JR; Chen J; Walker KA; Sullivan KJ; Thyagarajan B; Mielke MM; Lutsey PL; Knopman D; Gottesman RF; Sharrett AR; Coresh J; Mosley TH; Palta P
    JAMA; 2024 Oct; 332(15):1258-1269. PubMed ID: 39068543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study.
    de Wolf F; Ghanbari M; Licher S; McRae-McKee K; Gras L; Weverling GJ; Wermeling P; Sedaghat S; Ikram MK; Waziry R; Koudstaal W; Klap J; Kostense S; Hofman A; Anderson R; Goudsmit J; Ikram MA
    Brain; 2020 Apr; 143(4):1220-1232. PubMed ID: 32206776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging.
    Mielke MM; Hagen CE; Wennberg AMV; Airey DC; Savica R; Knopman DS; Machulda MM; Roberts RO; Jack CR; Petersen RC; Dage JL
    JAMA Neurol; 2017 Sep; 74(9):1073-1080. PubMed ID: 28692710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease.
    Janelidze S; Berron D; Smith R; Strandberg O; Proctor NK; Dage JL; Stomrud E; Palmqvist S; Mattsson-Carlgren N; Hansson O
    JAMA Neurol; 2021 Feb; 78(2):149-156. PubMed ID: 33165506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two novel blood-based biomarker candidates measuring degradation of tau are associated with dementia: A prospective study.
    Neergaard JS; Dragsbæk K; Christiansen C; Karsdal MA; Brix S; Henriksen K
    PLoS One; 2018; 13(4):e0194802. PubMed ID: 29641555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential associations of plasma lipids with incident dementia and dementia subtypes in the 3C Study: A longitudinal, population-based prospective cohort study.
    Schilling S; Tzourio C; Soumaré A; Kaffashian S; Dartigues JF; Ancelin ML; Samieri C; Dufouil C; Debette S
    PLoS Med; 2017 Mar; 14(3):e1002265. PubMed ID: 28350817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
    Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study.
    Sundelöf J; Giedraitis V; Irizarry MC; Sundström J; Ingelsson E; Rönnemaa E; Arnlöv J; Gunnarsson MD; Hyman BT; Basun H; Ingelsson M; Lannfelt L; Kilander L
    Arch Neurol; 2008 Feb; 65(2):256-63. PubMed ID: 18268197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
    Fagan AM; Roe CM; Xiong C; Mintun MA; Morris JC; Holtzman DM
    Arch Neurol; 2007 Mar; 64(3):343-9. PubMed ID: 17210801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease.
    Kester MI; Teunissen CE; Crimmins DL; Herries EM; Ladenson JH; Scheltens P; van der Flier WM; Morris JC; Holtzman DM; Fagan AM
    JAMA Neurol; 2015 Nov; 72(11):1275-80. PubMed ID: 26366630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging.
    Lieb W; Beiser AS; Vasan RS; Tan ZS; Au R; Harris TB; Roubenoff R; Auerbach S; DeCarli C; Wolf PA; Seshadri S
    JAMA; 2009 Dec; 302(23):2565-72. PubMed ID: 20009056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma biomarkers for predicting the development of dementia in a community-dwelling older Japanese population.
    Ohara T; Tatebe H; Hata J; Honda T; Shibata M; Matsuura S; Mikami T; Maeda T; Ono K; Mimura M; Nakashima K; Iga JI; Takebayashi M; Tokuda T; Ninomiya T;
    Psychiatry Clin Neurosci; 2024 Jun; 78(6):362-371. PubMed ID: 38606661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Plasma YKL-40 With MRI, CSF, and Cognitive Markers of Brain Health and Dementia.
    Pase MP; Himali JJ; Puerta R; Beiser AS; Gonzales MM; Satizabal CL; Yang Q; Aparicio HJ; Kojis DJ; Decarli CS; Lopez OL; Longstreth W; Gudnason V; Mosley TH; Bis JC; Fohner A; Psaty BM; Boada M; García-González P; Valero S; Marquié M; Tracy R; Launer LJ; Ruiz A; Fornage M; Seshadri S
    Neurology; 2024 Feb; 102(4):e208075. PubMed ID: 38290090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and alzheimer disease: results from the Framingham Heart Study.
    van Himbergen TM; Beiser AS; Ai M; Seshadri S; Otokozawa S; Au R; Thongtang N; Wolf PA; Schaefer EJ
    Arch Neurol; 2012 May; 69(5):594-600. PubMed ID: 22213409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Kidney Function With Development of Alzheimer Disease and Other Dementias and Dementia-Related Blood Biomarkers.
    Stocker H; Beyer L; Trares K; Perna L; Rujescu D; Holleczek B; Beyreuther K; Gerwert K; Schöttker B; Brenner H
    JAMA Netw Open; 2023 Jan; 6(1):e2252387. PubMed ID: 36692879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.
    Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K
    JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
    Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
    JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.